text
"[""\nXII. 상세표\n1. 연결대상 종속회사 현황(상세)\n☞ 본문 위치로 이동\n(단위 : 천원)\n상호\n설립일\n주소\n주요사업\n최근사업연도말자산총액\n지배관계 근거\n주요종속회사 여부\n셀트리온제약\n2000.11.17\n충청북도 청주시 청원군 오창읍 2산단로 82\n의약품 제조ㆍ판매\n641,643,568\xa0\n지분 50%초과보유\n해당\n셀트리온유럽\n2009.07.21\n4th Floor, 15 Basinghall Street, London, EC2V 5BR, UK\n바이오의약품 임상시험\n2\xa0\n지분 50%초과보유\n미해당\nCelltrion Global Safety Data Center\n2018.05.23\nUnit 2201, 22th floor, One Global Place, 5th Avenue Corner 25th Street,Bonifacio Global City, Taguig, 1634 Metro Manila, Philippines\n글로벌의약품 안전성데이터 관리\n3,286,670\xa0\n지분 50%초과보유\n미해당\nCelltrion Biopharma\n2019.02.13\n1st Floor, 6 Lapp's Quay, Cork, T12 VY7W, Ireland\n바이오의약품 임상시험\n0\xa0\n지분 50%초과보유\n미해당\nCelltrion Group Hongkong(*1)\n2019.03.15\nUnit 1101, Enterprise Square, Tower 1,9 Sheung Yuet Road, Kowloon Bay, Kowloon, Hongkong\n바이오의약품 중국사업\n0\xa0\n지분 50%초과보유\n미해당\nShanghai Vcell Biotech(*2)\n2019.04.09\n上海市浦東新區南彙新城鎭芦潮港路1969號219室\n바이오의약품 임상시험등 연구개발\n1,446,835\xa0\n지분 50%초과보유\n미해당\nCelltrion Asia Pacific PTE\n2020.08.12\n6 Eu Tong Sen Street #11-10C, The Central Singapore, 059817\n케미컬의약품 판매및 연구개발\n364,606,829\xa0\n지분 50%초과보유\n해당\nCelltrion Healthcare ILAC SANAYI TICARET LIMITED SIRKETI(*3)\n2010.09.16\nPark Plaza, Maslak Mahallesi Eski Buyukdere Cad.No: 14 Kat 7D: 19 34396 Sarıyer, Istanbul, Turkey\n의약품 제조 및 도소매업\n56,221,910\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare Hungary, Kft.(*3)\n2010.05.10\nVaci ut 1-3, WestEnd Office Building B torony,H-1062 Budapest, Hungary\n의약품 제조 및 도소매업\n1,290,432,441\xa0\n지분 50%초과보유\n해당\nCelltrion Healthcare Philippines Inc.(*3)\n2012.05.16\nUnit 2206 Philippine Axa Life Centre, Sen.Gil Puyat Avenue,1200 Makati City, Philippines\n의약품 도소매업\n4,421,890\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare Malaysia SDN BHD(*3)\n2012.06.13\nUnit 32-01, Level 32 Tower B, The Vertical Corporate Towers,Avenue 10 Bangsar South, No.8 Jalan Kerinchi, 59200 Kuala Lumpur\n의약품 도소매업\n611,615\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare Hong Kong Limited(*3)\n2012.05.10\nSuite 3305, 33rd Floor, Tower 5, The Gateway,Harbour City,15 Canton Road, Tsim Sha Tsui, Kowloon\n의약품 도소매업\n15,723,664\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare (Thailand) Co., Ltd.(*3)\n2012.05.25\nNo. 18 The Unicorn, Unit 1107-1111, 11thFloor Phayathai Road,Kwaeng Thungphayathai, Khet Ratchathewi, Bangkok\n의약품 도소매업\n50,979,399\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare Distribuicao deProdutos Farmaceuticos do Brasil LTDA(*3)\n2012.07.13\nRua Santo Antonio, 175, Piso Terreo, Centro, Caieiras, Sao Paulo, Brazil\n의약품 도소매업\n124,823,810\xa0\n지분 50%초과보유\n해당\nCelltrion Healthcare Singapore Private Limited(*3)\n2012.06.01\n65, Chulia Street #41-02 OCBC Centre, Singapore 049513\n의약품 도소매업\n8,302,376\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare Japan K.K.(*3)\n2014.07.09\n104－0033, Tokyo-to, Chuo-ku, Shinkawa 1-16-3,Sumitomo Fudosan Kayabacho Bldg. 3rd floor\n의약품 제조 및 도소매업\n39,868,290\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare Taiwan Limited(*3)\n2016.11.10\n3F.-1, No. 97, Songren Rd., Xinyi Dist., Taipei City 110050,Taiwan (R.O.C.) \xa0(postal code : 110050)\n의약품 도소매업\n13,580,326\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare Netherlands B.V.(*3)\n2018.02.06\nStrawinskylaan 625, 1077XX Amsterdam, Netherlands\n의약품 도소매업\n63,027,907\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare Australia Pty Ltd(*3)\n2018.04.05\nSuite 1303 Level 13, 31 New Market Street, Sydney NSW 2000, Australia\n의약품 도소매업\n20,575,439\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare Colombia S.A.S.(*3)\n2018.08.17\nCalle 37 No. 24-28, Bogota D.C., Colombia\n의약품 도소매업\n47,063,709\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare Canada Ltd.(*3)\n2019.06.25\n6345 197 Street, Langley, Britishy Columbia, V2Y 1K8, Canada\n의약품 도소매업\n10,787,611\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare United Kingdom Limited.(*3)(*4)\n2018.11.19\nThe Switch, 1-7 The Grove, Slough, SL1 1QP, UK\n의약품 도소매업\n68,905,909\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare Ireland Limited(*3)(*4)\n2018.11.23\nSuite 26, Arrow Building, Old Belgard Road, Tallaght,Dublin, D24 ND70, Ireland\n의약품 도소매업\n15,732,606\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare Denmark ApS(*3)(*4)\n2018.11.27\nC/O Regus Fuglevangsvej 11 1962 Frederiksberg C, Denmark\n의약품 도소매업\n96,335\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare Austria GmbH(*3)(*4)\n2018.12.21\nQBC 4, Am Belvedere 4, Vienna 1100, Austria\n의약품 도소매업\n129,992\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare Deutschland GmbH(*3)(*4)\n2019.01.14\nRathausplatz 12, 61348 Bad Homburg vor der Hohe, Germany\n의약품 도소매업\n11,803,082\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare Italy S.r.l(*3)(*4)\n2019.01.08\nVIA GALVANI LUIGI 24 CAP 20124, MILAN, Italy\n의약품 도소매업\n55,024,849\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare Belgium Sprl.(*3)(*4)\n2019.01.15\nIkaroslaan 1, 1930 Zaventem, Belgium\n의약품 도소매업\n2,103,118\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare Norway AS(*3)(*4)\n2019.03.04\nC/O Spaces Aker Brygge Fjordalleen 16 0250 OSLO, Norway\n의약품 도소매업\n117,646\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare France SAS(*3)(*4)\n2019.04.03\n14 rue Cambaceres, 75008 Paris, France\n의약품 도소매업\n136,109,502\xa0\n지분 50%초과보유\n해당\nCelltrion Healthcare Finland Oy(*3)(*4)\n2019.05.28\nc/o SPACES Mannerheiminaukio 1 A, 00100 Helsinki, Finland\n의약품 도소매업\n3,251,581\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare New Zealand Limited(*3)(*5)\n2018.10.25\nMoore Stephens Markhams Auckland, Floor 1, 103 Carlton Gore Road,Newmarket, Auckland 1023, NZ\n의약품 도소매업\n1,103,923\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare De Mexico S.A.de C.V.(*3)(*6)\n2018.12.20\nAdolfo Prieto 1213, Del Valle, Benito Juarez,Avenida Angel Urraza y Porfirio Diaz, Mexico\n의약품 도소매업\n29,248,337\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare Chile SpA(*3)(*6)\n2018.12.18\nAv. Providencia, Nro. 1760, Depto 603, Provincia, Santiago, Chile\n의약품 도소매업\n1,663,580\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare Peru S.A.C.(*3)(*6)\n2019.02.19\nAv. El Polo N° 670 Ofic. 301 Block A - Santiago de Surco, Peru\n의약품 도소매업\n7,562,032\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare Argentina S.A.U.(*3)(*6)\n2019.01.17\nSarmiento 663. 3er. Piso. Buenos Aires City, Argentina\n의약품 도소매업\n293\xa0\n지분 50%초과보유\n미해당\nCelltrion USA, Inc.(*3)\n2018.07.26\n1 EVERTRUST PLAZA SUITE 1207 JERSEY CITY, NEW JERSEY 07302\n의약품 도소매업\n95,133,591\xa0\n지분 50%초과보유\n해당\nCelltrion Healthcare Czech Republic s.r.o.(*3)(*4)\n2022.08.04\nBucharova 2657/12, 158 00, Praha 5 - Stod?lky\n의약품 도소매업\n1,479,245\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare Romania S.R.L.(*3)(*4)\n2022.11.10\nBucuresti Sectorul 1, Calea Floreasca, Nr. 169*A,Birou 2058-2059, Corp A, Etaj 4\n의약품 도소매업\n794,833\xa0\n지분 50%초과보유\n미해당\nCelltrion Healthcare Poland Republic s.r.o.(*3)(*4)\n2023.11.03\nUL.DUBOIS 114/116, 93-465 LODZ, Poland\n의약품 도소매업\n332,546\xa0\n지분 50%초과보유\n미해당\n(*1) 당기 중 청산되어 종속기업에서 제외되었습니다.\n(*2) 당기 중 Celltrion Group Hongkong이 보유하고 있던 지분을 신규취득하였습니다.\n(*3) 당기 중 셀트리온헬스케어를 흡수 합병함에 따라 추가되었습니다.\n(*4) Celltrion Healthcare Hungary, Kft.의 종속기업입니다.\n(*5) Celltrion Healthcare Australia Pty Ltd의 종속기업입니다.\n(*6) Celltrion Healthcare Colombia S.A.S의 종속기업입니다.\n2. 계열회사 현황(상세)\n☞ 본문 위치로 이동\n(기준일 :\xa0\n2023년 12월 31일\n)\n(단위 : 사)\n상장여부\n회사수\n기업명\n법인등록번호\n상장\n2\n(주)셀트리온\n135011-0034038\n(주)셀트리온제약\n110111-2112764\n비상장\n6\n(주)셀트리온홀딩스\n120111-0551178\n(주)셀트리온엔터테인먼트\n110111-4767757\n(주)셀트리온스킨큐어\n110111-1995723\n(주)티에스이엔씨\n120111-0379223\n(주)서린홀딩스\n110111-7727253\n(주)서원디앤디\n110111-7026332\n3. 타법인출자 현황(상세)\n☞ 본문 위치로 이동\n(기준일 :\xa0\n2023년 12월 31일\n)\n(단위 : 천원, 주, %)\n법인명\n상장여부\n최초취득일자\n출자목적\n최초취득금액\n기초잔액\n증가(감소)\n기말잔액\n최근사업연도재무현황\n수량\n지분율\n장부가액\n취득(처분)\n평가손익\n수량\n지분율\n장부가액\n총자산\n당기순손익\n수량\n금액\n바이오톡스텍\n상장\n2009.07.28\n단순투자\n2,025,000\xa0\n1,631,134\xa0\n11.12\xa0\n13,277,431\xa0\n0\xa0\n0\xa0\n-3,229,645\xa0\n1,631,134\xa0\n10.22\xa0\n10,047,786\xa0\n130,604,587\xa0\n-7,727,054\xa0\nA&G Pharmaceutical, Inc.\n비상장\n2006.07.14\n단순투자\n2,676,548\xa0\n987,889\xa0\n16.51\xa0\n116,349\xa0\n0\xa0\n0\xa0\n0\xa0\n987,889\xa0\n16.51\xa0\n116,349\xa0\n6,070,207\xa0\n1,414,454\xa0\n매일방송\n비상장\n2011.03.17\n단순투자\n1,000,000\xa0\n250,981\xa0\n0.48\xa0\n1,475,167\xa0\n0\xa0\n0\xa0\n0\xa0\n250,981\xa0\n0.48\xa0\n1,475,167\xa0\n443,353,400\xa0\n6,073,846\xa0\n제이티비씨\n비상장\n2017.09.20\n단순투자\n500,000\xa0\n100,000\xa0\n0.09\xa0\n43,725\xa0\n0\xa0\n0\xa0\n0\xa0\n100,000\xa0\n0.09\xa0\n43,725\xa0\n484,818,324\xa0\n-58,913,727\xa0\nAbpro Corporation\n비상장\n2022.09.26\n단순투자\n2,816,797\xa0\n111,111\xa0\n0.67\xa0\n2,816,797\xa0\n0\xa0\n0\xa0\n0\xa0\n111,111\xa0\n0.65\xa0\n2,816,797\xa0\n15,003,881\xa0\n-14,079,253\xa0\nDantari\n비상장\n2022.07.01\n단순투자\n491,016\xa0\n910,615\xa0\n1.62\xa0\n491,016\xa0\n0\xa0\n-147,305\xa0\n0\xa0\n910,615\xa0\n1.62\xa0\n343,711\xa0\n9,993,892\xa0\n-12,977,709\xa0\nTriunfo\n비상장\n2023.04.06\n단순투자\n0\xa0\n0\xa0\n0.00\xa0\n0\xa0\n910,615\xa0\n147,305\xa0\n0\xa0\n910,615\xa0\n1.46\xa0\n147,305\xa0\n1,251,281\xa0\n-5,682,566\xa0\n피노바이오\n비상장\n2022.10.31\n단순투자\n2,000,310\xa0\n66,900\xa0\n1.81\xa0\n2,000,310\xa0\n0\xa0\n0\xa0\n0\xa0\n66,900\xa0\n1.20\xa0\n2,000,310\xa0\n5,900,354\xa0\n-15,362,684\xa0\nHEM Pharma\n비상장\n2023.11.22\n단순투자\n1,000,006\xa0\n0\xa0\n0.00\xa0\n0\xa0\n47,893\xa0\n1,000,006\xa0\n0\xa0\n47,893\xa0\n0.77\xa0\n1,000,006\xa0\n24,114,126\xa0\n-2,356,895\xa0\n바스젠바이오\n비상장\n2023.04.24\n단순투자\n1,050,000\xa0\n0\xa0\n0.00\xa0\n0\xa0\n7,000\xa0\n1,050,000\xa0\n0\xa0\n7,000\xa0\n1.49\xa0\n1,050,000\xa0\n6,330,623\xa0\n-10,955,693\xa0\n프리미어 글로벌이노베이션 1호\n비상장\n2017.06.15\n단순투자\n250,000\xa0\n2,590\xa0\n6.67\xa0\n2,898,171\xa0\n-263\xa0\n-263,247\xa0\n587,236\xa0\n2,327\xa0\n6.67\xa0\n3,222,160\xa0\n48,700,744\xa0\n2,552,364\xa0\n프리미어 글로벌이노베이션 2호\n비상장\n2020.11.05\n단순투자\n250,000\xa0\n3,700\xa0\n5.56\xa0\n3,555,844\xa0\n656\xa0\n656,500\xa0\n-61,145\xa0\n4,356\xa0\n5.56\xa0\n4,151,199\xa0\n75,163,949\xa0\n-1,757,199\xa0\n셀트리온 유럽\n비상장\n2009.07.21\n경영참여\n2\xa0\n1\xa0\n100.00\xa0\n2\xa0\n0\xa0\n0\xa0\n0\xa0\n1\xa0\n100.00\xa0\n2\xa0\n2\xa0\n0\xa0\n셀트리온제약\n상장\n2013.04.23\n경영참여\n50,057,259\xa0\n20,678,107\xa0\n54.85\xa0\n255,342,176\xa0\n1,033,905\xa0\n0\xa0\n0\xa0\n21,712,012\xa0\n54.81\xa0\n255,342,176\xa0\n641,643,568\xa0\n21,264,989\xa0\nCelltrion Global Safety Data Center\n비상장\n2018.05.23\n경영참여\n1,106,930\xa0\n580,563\xa0\n99.99\xa0\n1,204,581\xa0\n0\xa0\n0\xa0\n0\xa0\n580,563\xa0\n99.99\xa0\n1,204,581\xa0\n3,286,670\xa0\n35,264\xa0\nCelltrion Asia Pacific PTE\n비상장\n2020.11.23\n경영참여\n315,987,120\xa0\n283,600,000\xa0\n100.00\xa0\n315,987,120\xa0\n0\xa0\n0\xa0\n0\xa0\n283,600,000\xa0\n100.00\xa0\n315,987,120\xa0\n364,606,829\xa0\n-7,208,344\xa0\nCelltrion Group Hongkong ltd\n비상장\n2019.04.01\n경영참여\n5,680,500\xa0\n7,023,270\xa0\n70.00\xa0\n2,340,622\xa0\n-7,023,270\xa0\n-2,340,622\xa0\n0\xa0\n0\xa0\n0.00\xa0\n0\xa0\n0\xa0\n-668,850\xa0\nVcell Shanghai Biotech\n비상장\n2023.01.19\n경영참여\n1,425,590\xa0\n0\xa0\n0.00\xa0\n0\xa0\n0\xa0\n1,425,590\xa0\n0\xa0\n0\xa0\n100.00\xa0\n1,425,590\xa0\n1,446,835\xa0\n-5,393\xa0\nCelltrion Healthcare ILAC SANAYITICARET LIMITED SIRKETI\n비상장\n2023.12.28\n경영참여\n23,664,284\xa0\n0\xa0\n0.00\xa0\n0\xa0\n1,337,866\xa0\n15,505,212\xa0\n0\xa0\n1,337,866\xa0\n100.00\xa0\n15,505,212\xa0\n56,221,910\xa0\n-1,690,514\xa0\nCelltrion Healthcare Hungary, Kft.\n비상장\n2023.12.28\n경영참여\n704,771,752\xa0\n0\xa0\n0.00\xa0\n0\xa0\n0\xa0\n704,771,752\xa0\n0\xa0\n0\xa0\n100.00\xa0\n704,771,752\xa0\n1,290,432,441\xa0\n19,221,137\xa0\nCelltrion Healthcare Philippines Inc.\n비상장\n2023.12.28\n경영참여\n935,128\xa0\n0\xa0\n0.00\xa0\n0\xa0\n389,990\xa0\n935,128\xa0\n0\xa0\n389,990\xa0\n99.99\xa0\n935,128\xa0\n4,421,890\xa0\n120,206\xa0\nCelltrion Healthcare Malaysia SDN BHD\n비상장\n2023.12.28\n경영참여\n161,045\xa0\n0\xa0\n0.00\xa0\n0\xa0\n538,336\xa0\n161,045\xa0\n0\xa0\n538,336\xa0\n100.00\xa0\n161,045\xa0\n611,615\xa0\n30,655\xa0\nCelltrion Healthcare Hong Kong Limited\n비상장\n2023.12.28\n경영참여\n376,202\xa0\n0\xa0\n0.00\xa0\n0\xa0\n2,586,895\xa0\n376,202\xa0\n0\xa0\n2,586,895\xa0\n100.00\xa0\n376,202\xa0\n15,723,664\xa0\n542,177\xa0\nCelltrion Healthcare (Thailand) Co., Ltd.\n비상장\n2023.12.28\n경영참여\n2,586,240\xa0\n0\xa0\n0.00\xa0\n0\xa0\n20,199,998\xa0\n2,586,240\xa0\n0\xa0\n20,199,998\xa0\n100.00\xa0\n2,586,240\xa0\n50,979,399\xa0\n1,434,748\xa0\nCelltrion Healthcare Distribuicao deProdutos Farmaceuticos do Brasil LTDA\n비상장\n2023.12.28\n경영참여\n64,555,806\xa0\n0\xa0\n0.00\xa0\n0\xa0\n14,692,902\xa0\n64,555,806\xa0\n0\xa0\n14,692,902\xa0\n100.00\xa0\n64,555,806\xa0\n124,823,810\xa0\n30,686,271\xa0\nCelltrion Healthcare Singapore Private Limited\n비상장\n2023.12.28\n경영참여\n178,945\xa0\n0\xa0\n0.00\xa0\n0\xa0\n200,000\xa0\n178,944\xa0\n0\xa0\n200,000\xa0\n100.00\xa0\n178,944\xa0\n8,302,376\xa0\n123,713\xa0\nCelltrion Healthcare Japan K.K.\n비상장\n2023.12.28\n경영참여\n23,996,341\xa0\n0\xa0\n0.00\xa0\n0\xa0\n484,060\xa0\n23,996,341\xa0\n0\xa0\n484,060\xa0\n100.00\xa0\n23,996,341\xa0\n39,868,290\xa0\n944,427\xa0\nCelltrion Healthcare Taiwan Limited\n비상장\n2023.12.28\n경영참여\n0\xa0\n0\xa0\n0.00\xa0\n0\xa0\n0\xa0\n0\xa0\n0\xa0\n0\xa0\n100.00\xa0\n0\xa0\n13,580,326\xa0\n328,311\xa0\nCelltrion Healthcare Netherlands B.V.\n비상장\n2023.12.28\n경영참여\n224,538\xa0\n0\xa0\n0.00\xa0\n0\xa0\n100,101\xa0\n224,538\xa0\n0\xa0\n100,101\xa0\n100.00\xa0\n224,538\xa0\n63,027,907\xa0\n885,848\xa0\nCelltrion Healthcare Australia Pty Ltd\n비상장\n2023.12.28\n경영참여\n2,201,659\xa0\n0\xa0\n0.00\xa0\n0\xa0\n4,764,010\xa0\n2,201,659\xa0\n0\xa0\n4,764,010\xa0\n100.00\xa0\n2,201,659\xa0\n20,575,439\xa0\n5,384,581\xa0\nCelltrion Healthcare Colombia S.A.S.\n비상장\n2023.12.28\n경영참여\n18,647,246\xa0\n0\xa0\n0.00\xa0\n0\xa0\n59,198,321\xa0\n18,647,246\xa0\n0\xa0\n59,198,321\xa0\n100.00\xa0\n18,647,246\xa0\n47,063,709\xa0\n-1,649,817\xa0\nCelltrion Healthcare Canada Ltd.\n비상장\n2023.12.28\n경영참여\n196,078,894\xa0\n0\xa0\n0.00\xa0\n0\xa0\n186,430,000\xa0\n196,078,894\xa0\n0\xa0\n186,430,000\xa0\n100.00\xa0\n196,078,894\xa0\n10,787,611\xa0\n-10,783,918\xa0\nCelltrion USA, Inc.\n비상장\n2023.12.28\n경영참여\n3,254,735,180\xa0\n0\xa0\n0.00\xa0\n0\xa0\n3,050\xa0\n3,354,039,677\xa0\n0\xa0\n3,050\xa0\n100.00\xa0\n3,354,039,677\xa0\n95,133,591\xa0\n-20,644,112\xa0\n2014 성장사다리-IMM벤처펀드\n비상장\n2014.08.11\n일반투자\n2,000,000\xa0\n1,617\xa0\n20.00\xa0\n800,644\xa0\n-1,617\xa0\n-800,644\xa0\n0\xa0\n0\xa0\n0.00\xa0\n0\xa0\n0\xa0\n-2,796,786\xa0\n미래에셋셀트리온신성장투자조합 1호\n비상장\n2017.03.31\n일반투자\n6,250,000\xa0\n458\xa0\n50.00\xa0\n45,750,000\xa0\n-30\xa0\n-3,000,000\xa0\n0\xa0\n428\xa0\n50.00\xa0\n42,750,000\xa0\n105,516,402\xa0\n-7,436,819\xa0\n미래에셋셀트리온바이오생태계육성펀드\n비상장\n2021.12.30\n일반투자\n5,000,000\xa0\n12,500\xa0\n38.46\xa0\n12,500,000\xa0\n7,500\xa0\n7,500,000\xa0\n0\xa0\n20,000\xa0\n38.46\xa0\n20,000,000\xa0\n49,894,800\xa0\n-1,206,265\xa0\n아주-Solasta Life Science 4.0펀드\n비상장\n2022.05.16\n일반투자\n5,000,000\xa0\n12,500,000,000\xa0\n44.25\xa0\n12,500,000\xa0\n12,500,000,000\xa0\n12,500,000\xa0\n0\xa0\n25,000,000,000\xa0\n44.25\xa0\n25,000,000\xa0\n53,670,253\xa0\n-2,927,582\xa0\nIksuda Therapeutics Limited\n비상장\n2021.06.01\n경영참여\n9,031,863\xa0\n717,112\xa0\n16.33\xa0\n9,031,863\xa0\n594,106\xa0\n8,879,530\xa0\n0\xa0\n1,311,218\xa0\n22.38\xa0\n17,911,393\xa0\n31,801,554\xa0\n-18,854,116\xa0\n싸이런 테라퓨틱스\n비상장\n2023.05.01\n일반투자\n2,264,621\xa0\n0\xa0\n0.00\xa0\n0\xa0\n88,359\xa0\n2,460,221\xa0\n0\xa0\n88,359\xa0\n22.15\xa0\n2,460,221\xa0\n2,094,401\xa0\n-620,710\xa0\n셀트리온충북대바이오메딕스\n비상장\n2018.07.18\n경영참여\n100,000\xa0\n20,000\xa0\n50.00\xa0\n100,000\xa0\n0\xa0\n0\xa0\n0\xa0\n20,000\xa0\n50.00\xa0\n100,000\xa0\n118,613\xa0\n-9,410\xa0\n합 계\n12,816,698,548\xa0\n-\n682,231,818\xa0\n12,786,590,383\xa0\n4,413,326,018\xa0\n-2,703,554\xa0\n25,603,288,931\xa0\n-\n5,092,854,282\xa0\n4,346,939,273\xa0\n-115,272,425\xa0\n""]"
